OBJECTIVE: Weight gain is a prominent effect of most atypical antipsychotic drugs (AAPDs); yet, the mechanisms are not fully understood and no well-established mouse models exist for investigating the mechanisms. Thus, we developed a mouse model to evaluate the effects of AAPDs on eating, body weight (BW), and body composition. METHODS: Female C57BL/6J mice were used to test olanzapine, quetiapine, ziprasidone, and risperidone. Mice were acclimated to individual housing, given ad libitum access to chow and water, dosed with placebo peanut butter pills for 1 week, and then dosed daily with AAPD-laced peanut butter pills for 4 weeks. Weekly food intakes and BWs were measured, and body compositions were determined at the end of each experiment. RESULTS: After 4 weeks of treatment, olanzapine, quetiapine, ziprasidone, and risperidone caused significant weight increases, but only olanzapine and quetiapine were associated with significantly increased food intake. Body composition data revealed that olanzapine-treated mice had more relative fat mass and risperidone-treated mice had more relative lean mass than did control mice. Quetiapine and ziprasidone did not significantly affect relative body composition even though BW was increased. CONCLUSIONS: Oral AAPD administration causes increased BW in female mice. Our mouse model of AAPD-induced weight gain resembles the human response to these medications and will be used to investigate the mechanisms for weight gain and fat accumulation.
Introduction
Second-generation atypical antipsychotic drugs (AAPDs), such as olanzapine, quetiapine, ziprasidone, and risperidone, are commonly used for treating symptoms of schizophrenia. [1] [2] [3] These newer AAPDs produce fewer side-effects than did the initial AAPDs, especially clozapine, 4 but are not without side-effects. The most commonly reported sideeffect, possibly related to patient noncompliance, 5 is weight gain. [6] [7] [8] Patients with schizophrenia gain weight after short times on AAPDs, 9 and long-term AAPD administration induces weight gains of at least 5 kg in upto 50% of patients. 8 This degree of weight gain increases the health risks associated with obesity. 10, 11 A number of laboratories have attempted to produce a model of AAPD-induced weight gain (Table 1) , but reports of such efforts have had the following limitations: (a) few models consider more than two individual drugs; (b) no program has used the C57BL/6J mouse as the model, important because most genetic and molecular work is carried out in mice; (c) no studies have used chronic oral administration, the route most commonly used in humans, via a system that neither stresses the animal nor fails to control the dose; (d) few reports have had clearly consistent findings; and (e) few programs reported food intake and body composition results in addition to body weight (BW).
Acute administration of AAPDs in rodents has been evaluated by others. Intraperitoneal (i.p.) injections of clozapine (CLZ) increased 24-h intakes of dry food pellets by male Sprague-Dawley rats, whereas olanzapine and risperidone did not affect food intake. 12 I.p. injections of CLZ and olanzapine did not increase food intake in male Lister hooded rats. 13 The effects of olanzapine and risperidone were different when animals were offered palatable test foods. Olanzapine administered i.p. significantly increased 30-min meal size of a fat emulsion (Intralipid, 10% emulsion of fatty acids) in rats, 14 and olanzapine and risperidone administered i.p. increased the food intake (10% sucrose added to standard mouse pellets) in female mice for 4 h after injection. 15 Several studies investigated olanzapine-and risperidone-induced weight gain in rodents, but none have investigated the effects of quetiapine and ziprasidone on food intake and BW. Reports on the effects of chronic administration of AAPDs on weight gain or hyperphagia are inconsistent. Weight gain and hyperphagia were found in female rats treated with sulpiride [16] [17] [18] and risperidone, 19 but not in male rats treated with sulpiride, 20 risperidone, 19 or olanzapine. 21 Subcutaneous injections of risperidone for 21 days increased the food intake (12% fat in diet) and rate of BW gain in 8-weekold male Sprague-Dawley rats. 22 Female Wistar rats treated orally (via gavage) with olanzapine gained significantly more weight and ate more than did placebo-treated rats after 3 weeks of treatment. 21 Female Wistar rats (age and % fat in diet not reported) administered i.p. olanzapine twice daily for 19 days gained significantly more weight than did controls. 23 Chronic administration of olanzapine by gavage or i.p. injections to female but not male Wistar rats appears to cause some hyperphagia and weight gain. Body composition data after chronic oral administration of AAPDs were not reported. These conflicting data suggest that, under some conditions, acute administration of AAPDs may increase food intake in rodents and in some cases chronic administration will cause weight gain. However, more appropriate animal models are needed in order to analyze the underlying mechanisms of AAPD-induced weight gain. In this report, we describe the development of a mouse model of AAPDinduced weight gain.
Methods and procedures

Drugs
Pfizer Pharmaceutical (Groton, CT, USA) generously donated ziprasidone, and risperidone was purchased from Sigma (St Louis, MO, USA). Olanzapine and quetiapine are not available commercially; therefore, the drugs were extracted from pharmaceutical tablets.
Extraction of olanzapine and quetiapine. We extracted olanzapine from Zyprexa s (Eli Lilly & Company, Indianapolis, IN, USA) and quetiapine from Seroquel s (AstraZeneca Pharmaceuticals LP, Wilmington, DE, USA) tablets using modifications of a published technique. 24 Tablets were pulverized using a mortar and pestle, and a slurry in water was used to dissolve binders and coating. Olanzapine was separated from water with ethyl acetate (Sigma). To make quetiapine soluble in ethyl acetate, the quetiapine solution was deprotonated with saturated sodium bicarbonate (pH ¼ 8). Solutions were filtered through a silica/celite pad several times. The organic layer (containing the drugs) was washed with water and brine, and excess sodium sulfate (Sigma) was added to dry the remaining water. Ethyl acetate was evaporated and the solids remaining were suspended in acetonitrile (Sigma). Recrystallization was allowed at room Preparation of treatment pills. Purified drugs were dissolved in heated (371C) peanut butter (Jif, Cincinnati, OH, USA) to achieve the target dosage, mixed for approximately 15 min, placed into plastic molds (100 mg corticosterone pellet molds, Ted Pella, Inc., Redding, CA, USA), and stored at À801C until treatment time. Doses were recalculated weekly based on group mean weights. Each mouse consumes the peanut butter pellet quickly and there is far less risk of stress or death using this approach compared to gavage.
Animals
Five experiments were performed on different mice in the same room. In each experiment, female C57BL/6J mice (Jackson Laboratories, Bar Harbor, ME, USA) received standard mouse food (Teklad Global 16% Protein Rodent Diet, Harlan, Madison, WI, USA) and water ad libitum. Room temperature was 22721C and lights were on a 12/12 light/ dark cycle (on at 0600 h). At approximately 10 weeks of age, mice were randomly assigned to groups using a pseudo random-number generator. Mice were acclimated to individual housing for 2 weeks and given 100 mg plain peanut butter pills daily for 1 week before starting treatment. (Pills were placed on water sipping tubes and consumed within 5 min.) The institutional animal care and use committee at the University of Alabama at Birmingham approved all procedures.
BW and food intake BWs were measured (70.1 g) weekly in all experiments with a portable electronic balance (OHAUS, Pine Brook, NJ, USA). Food intakes were measured (70.1 g) on two consecutive days during weeks 2 and 4 of experiment 1 and weekly for other experiments by subtracting the amount of food remaining after 48 h from the initial amount of food in hopper. Food spillage during experiments was minimal and was not included in analysis.
Body composition analysis
Body composition was determined by chemical carcass analysis. 25 Carcasses were thawed at room temperature and weighed to determine water loss due to freezing. Gastrointestinal tracts were removed and bodies were weighed to determine the eviscerated weight. For the determination of body water, the body was cut open and dried at 601C until a constant mass was achieved. The dried body was then ground and extracted with petroleum ether in a Soxhlet apparatus to determine fat mass and fat-free dry mass (FFDM). 26 FFDM was burned at 6001C overnight (minimum 8 h) to determine ash content. Total-carcass ash content was determined by multiplying the percentage of ash in the FFDM sample by the total FFDM of the carcass. Chemically derived lean tissue mass was calculated as fat-free mass minus ash content plus water (corrected for water loss during freezing). 
Statistical analysis
Food intakes and BW changes for 48 h were analyzed with one-way analysis of variance (experiments 1, 3-5) and Student t-tests (experiment 2). Post hoc analysis was performed with Fisher's least significant difference test (appropriate when only three groups are being compared). 27 Body composition data were analyzed using analysis of covariance with eviscerated BW being the covariate. The criterion for statistical significance was Po0.05 (two-tailed).
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The data met the parametric assumptions of normality of residuals and homoscedasticity.
Results
Experiment 1
Mice treated with 6 mg olanzapine/(kg BW Á day) ate more than mice treated with either placebo or 3 mg olanzapine/(kg BW Á day) during week 4 (F[2, 3] ¼ 6.56, P ¼ 0.004; Figure 1a ). Treatment with 6 mg olanzapine/(kg BW Á day) for 4 weeks significantly increased BW gain (F[2, 31] ¼ 4.42, P ¼ 0.021; Figure 1b ). Treatment with 6 mg olanzapine/(kg BW Á day) had no significant effect on food intake or BW gain during week 2, and 3 mg olanzapine/(kg BW Á day) had no significant effect on food intake or BW during weeks 2 or 4. Body composition of these animals was not analyzed. Figure 2b ). Eviscerated BWs were not different between groups; however, the olanzapine-treated mice had Figure 3b ). Mice treated with 30 mg quetiapine/(kg BW Á day) did not gain weight compared with control mice. No significant differences occurred between groups for any of the body composition variables measured (Table 2) .
Experiment 4
Treatment with risperidone did not affect food intake; however, both groups of mice treated with risperidone gained more weight than did control mice during weeks 1, Figure 4b ). Post hoc analysis revealed that low-dose ziprasidone did not significantly increase weight gain compared with the control. None of the body composition variables analyzed was different among groups.
Discussion
This study demonstrates an experimental protocol in which chronic oral AAPD treatment can increase food Antipsychotic drug-induced weight gain MB Cope et al intake and weight gain in female C57BL/6J mice. All AAPDs tested resulted in some increased weight over the 4 weeks of treatment, but only olanzapine-and quetiapine-treated mice significantly increased food intake. The hyperphagia and weight gain produced by chronic oral olanzapine treatment in mice have face validity as a model of the increased appetite and BW gain produced by olanzapine in patients with schizophrenia. 28 Likewise, quetiapine is associated with increased appetite and weight gain in children and adolescents with autistic disorder. 29 Thus, the hyperphagia and weight gain found in quetiapine-treated mice are similar to the findings in humans. The effects of these two agents on increasing appetite and weight in mice closely mimic the human response ( Figure 5 ). Drug administration and dosing were based on several factors. Drugs were offered in small amounts of peanut butter to avoid the stress of repeated gavage or chronic intragastric cannulation. Pilot acceptability tests were carried out to determine the maximum doses that the mice would quickly and reliably ingest. Preclinical data were used to avoid administration of toxic doses. Finally, we attempted to use mouse doses that were comparable to human doses, although this estimation is inexact because of the marked metabolic differences between the species and the wide range of doses used therapeutically. For example, ziprasidone is administered to humans at an initial daily dose of 20 mg twice daily with a maximum dose of 80 mg twice daily for some patients. Table 3 describes the doses that we used in this model.
AAPD-induced weight gain in rodents has been reported mostly in rats; only one has been conducted in Laca mice. 15 Our model is the first to show that chronic oral administration of AAPDs to female C57BL/6J mice will cause significant weight gain compared with placebo-treated mice. The olanzapine-and quetiapine-induced weight gain in our model is associated with hyperphagia, which has been Doses in parentheses are from mouse data. Antipsychotic drug-induced weight gain MB Cope et al documented in humans for both drugs. [28] [29] [30] Risperidone and ziprasidone caused significant weight gain but were not associated with hyperphagia, suggesting that these drugs may affect energy expenditure rather than intake in our model. More detailed energy expenditure measurements (activity levels, resting metabolic rate, and respiratory quotients) and cumulative food intake monitoring will be required to determine the effects of AAPDs on energy balance. Only olanzapine-treated mice had greater relative fat mass than did control mice (Table 2) . Although we do not have baseline body composition data to compare with end-point data, we can infer that olanzapine treatment causes mice to have a higher level of adiposity than controls. Future studies will be required to determine the amount of fat gained as a result of olanzapine treatment by measuring baseline body composition (eg, by dual energy X-ray absorptiometry (DXA)). Our findings agree with a human study that found an increase in adiposity associated with weight gain after olanzapine treatment. 31 An unexpected finding was that risperidone-treated mice had more lean tissue mass than did control mice even after correction for final eviscerated BW (Table 2) . Risperidone causes an increase in prolactin levels in humans compared with other antipsychotic drugs, 32 but whether this affects lean mass and bone mass has not been studied in detail. Most human studies reporting weight gain among patients have not reported body composition measures after chronic treatment with AAPDs, especially for risperidone and ziprasidone. Future mouse experiments will monitor changes in hormone levels and body composition from baseline to end point using hormone assays and DXA, respectively.
High-dose, but not low-dose, ziprasidone treatment was associated with significant weight gain, but not with changes in fat mass. Such weight gain has not been published before with any rodent model and does not usually occur in humans. 6 In one report, 12.4% of ziprasidone-treated patients, but only 5.1% of placebo-treated patients, gained weight. 10 Another report showed that switching a population with mental retardation from other AAPDs to ziprasidone caused weight loss. 33 Dosing experiments will be needed to determine whether the high dose of ziprasidone used in this model is excessive. It is important to note that the low-dose ziprasidone group did not have significant weight gain and mimics the human response more closely than the high-dose group. Common side-effects of most AAPDs in patients with schizophrenia are increased appetite and weight gainFan average of 4.5 kg (olanzapine), 2.1 kg (risperidone), and 0.04 kg (ziprasidone) 6 and 2.16 kg (quetiapine) 34 after 10 weeks of treatment. These weight gains elevate the risks of obesity-related health problems and may reduce compliance. [6] [7] [8] Our mouse model mimicking human weight gain ( Figure 5 ) may facilitate future investigations of the underlying mechanisms because of the technological advancesFknockouts, transgenics, microarray analysisFthat can be used with mice. In this report, we have described a model of AAPD-induced weight gain by accomplishing the following aims: (a) tested the effects of more than two individual AAPDs in this model; (b) used the C57BL/6J mouse as the model; (c) administered the drugs orally for a chronic period of time; (d) had clearly consistent findings; and (e) reported food intake and body composition results in addition to BW. It is not yet clear, however, how the drugs produced the particular changes in eating and BW that we report, why weight gain and food intake did not always co-vary, or why some drug effects did not appear to match those expected on the basis of the human clinical literature. In conclusion, this mouse model should be useful for physiological and genetic investigations of AAPD-induced increases in appetite and weight gain.
